A. Stuart Arbuckle's Insider Trades & SAST Disclosures
A. Stuart Arbuckle's most recent trade in Vertex Pharmaceuticals, Inc. was a trade of 7,071 Common Stock done at an average price of $479.6 . Disclosure was reported to the exchange on Feb. 26, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern A. Stuart Arbuckle.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 479.61 per share. | 26 Feb 2025 | 7,071 | 62,935 (0%) | 0% | 479.6 | 3,391,322 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 483.28 per share. | 24 Feb 2025 | 4,716 | 70,006 (0%) | 0% | 483.3 | 2,279,148 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 2,724 | 74,722 (0%) | 0% | 463.5 | 1,262,465 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 7,903 | 77,446 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 467.98 per share. | 10 Feb 2025 | 3,220 | 69,543 (0%) | 0% | 468.0 | 1,506,896 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 14,624 | 64,315 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 8,448 | 72,763 (0%) | 0% | 0 | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Stuart A. Arbuckle | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2024 | 3,000 | 0 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | Stuart A. Arbuckle | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2024 | 3,000 | 3,000 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Stuart A. Arbuckle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Stuart A. Arbuckle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 4,000 | 4,000 | - | - | Restricted Stock Units | |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 430.93 per share. | 15 May 2024 | 69 | 49,691 (0%) | 0% | 430.9 | 29,734 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Arbuckle A. Stuart | EVP, COO | Sale of securities on an exchange or to another person at price $ 425.70 per share. | 23 Feb 2024 | 5,034 | 49,691 (0%) | 0% | 425.7 | 2,142,974 | Common Stock |
| Vertex Pharmaceuticals, Inc. | A. Stuart Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 431.79 per share. | 23 Feb 2024 | 4,714 | 54,725 (0%) | 0% | 431.8 | 2,035,458 | Common Stock |
| Vertex Pharmaceuticals, Inc. | A. Arbuckle Stuart | EVP, COO | Sale of securities on an exchange or to another person at price $ 421.77 per share. | 21 Feb 2024 | 3,603 | 59,439 (0%) | 0% | 421.8 | 1,519,637 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart Arbuckle A. | EVP, COO | Sale of securities on an exchange or to another person at price $ 420.79 per share. | 16 Feb 2024 | 4,804 | 63,042 (0%) | 0% | 420.8 | 2,021,475 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Arbuckle A. Stuart | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 424.01 per share. | 16 Feb 2024 | 4,499 | 71,219 (0%) | 0% | 424.0 | 1,907,621 | Common Stock |
| Vertex Pharmaceuticals, Inc. | A. Arbuckle Stuart | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 420.58 per share. | 16 Feb 2024 | 3,373 | 67,846 (0%) | 0% | 420.6 | 1,418,616 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Arbuckle Stuart A. | EVP, COO | Sale of securities on an exchange or to another person at price $ 420.24 per share. | 09 Feb 2024 | 4,295 | 75,718 (0%) | 0% | 420.2 | 1,804,931 | Common Stock |
| Vertex Pharmaceuticals, Inc. | A. Arbuckle Stuart | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 09 Feb 2024 | 3,177 | 80,013 (0%) | 0% | 422.7 | 1,343,045 | Common Stock |
| Vertex Pharmaceuticals, Inc. | A. Stuart Arbuckle | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 11,210 | 74,742 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Arbuckle A. Stuart | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 8,448 | 83,190 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Arbuckle A. Stuart | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 6,976 | 63,532 (0%) | 0% | 0 | Common Stock | |
| Immunogen, Inc. | Stuart Arbuckle A. | Director | Grant, award, or other acquisition of securities at price $ 29.65 per share. | 29 Dec 2023 | 442 | 5,381 (0%) | 0% | 29.6 | 13,105 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart Arbuckle A. | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2023 | 8,603 | 0 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 399.00 per share. | 13 Dec 2023 | 8,603 | 56,556 (0%) | 0% | 399 | 3,432,597 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Arbuckle A. Stuart | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 187.53 per share. | 13 Dec 2023 | 8,603 | 65,159 (0%) | 0% | 187.5 | 1,613,321 | Common Stock |
| Immunogen, Inc. | Stuart A. Arbuckle | Director | Grant, award, or other acquisition of securities at price $ 18.87 per share. | 30 Jun 2023 | 695 | 4,112 (0%) | 0% | 18.9 | 13,115 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Stuart A. Arbuckle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Stuart A. Arbuckle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 3,000 | 3,000 | - | - | Restricted Stock Units | |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 349.00 per share. | 15 Jun 2023 | 8,603 | 56,556 (0%) | 0% | 349 | 3,002,447 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2023 | 8,603 | 8,603 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 187.53 per share. | 15 Jun 2023 | 8,603 | 65,159 (0%) | 0% | 187.5 | 1,613,321 | Common Stock |
| Immunogen, Inc. | Stuart A. Arbuckle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 19,597 | 19,597 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Stuart A. Arbuckle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 13,090 | 13,090 | - | - | Restricted Stock Unit | |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 329.82 per share. | 30 May 2023 | 82 | 56,556 (0%) | 0% | 329.8 | 27,045 | Common Stock |
| Immunogen, Inc. | Stuart A. Arbuckle | Director | Grant, award, or other acquisition of securities at price $ 3.84 per share. | 31 Mar 2023 | 3,417 | 3,417 (0%) | 0% | 3.8 | 13,121 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.12 per share. | 24 Feb 2023 | 4,714 | 61,590 (0%) | 0% | 289.1 | 1,362,912 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 287.16 per share. | 24 Feb 2023 | 3,834 | 57,756 (0%) | 0% | 287.2 | 1,100,971 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 288.92 per share. | 24 Feb 2023 | 800 | 56,556 (0%) | 0% | 288.9 | 231,136 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 287.59 per share. | 24 Feb 2023 | 400 | 57,356 (0%) | 0% | 287.6 | 115,036 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 294.29 per share. | 22 Feb 2023 | 1,378 | 66,898 (0%) | 0% | 294.3 | 405,532 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 295.38 per share. | 22 Feb 2023 | 394 | 66,504 (0%) | 0% | 295.4 | 116,380 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 292.86 per share. | 22 Feb 2023 | 300 | 68,276 (0%) | 0% | 292.9 | 87,858 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 296.31 per share. | 22 Feb 2023 | 200 | 66,304 (0%) | 0% | 296.3 | 59,262 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 291.84 per share. | 22 Feb 2023 | 129 | 68,576 (0%) | 0% | 291.8 | 37,647 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 292.85 per share. | 17 Feb 2023 | 4,498 | 71,107 (0%) | 0% | 292.8 | 1,317,239 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 293.74 per share. | 17 Feb 2023 | 1,100 | 69,441 (0%) | 0% | 293.7 | 323,114 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 294.58 per share. | 17 Feb 2023 | 736 | 68,705 (0%) | 0% | 294.6 | 216,811 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 292.77 per share. | 17 Feb 2023 | 545 | 70,541 (0%) | 0% | 292.8 | 159,560 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 291.00 per share. | 17 Feb 2023 | 21 | 71,086 (0%) | 0% | 291 | 6,111 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 299.13 per share. | 14 Feb 2023 | 2,003 | 77,739 (0%) | 0% | 299.1 | 599,157 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 300.09 per share. | 14 Feb 2023 | 1,734 | 76,005 (0%) | 0% | 300.1 | 520,356 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 296.85 per share. | 14 Feb 2023 | 901 | 80,302 (0%) | 0% | 296.9 | 267,462 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 295.84 per share. | 14 Feb 2023 | 800 | 81,203 (0%) | 0% | 295.8 | 236,672 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 298.14 per share. | 14 Feb 2023 | 560 | 79,742 (0%) | 0% | 298.1 | 166,958 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 300.89 per share. | 14 Feb 2023 | 400 | 75,605 (0%) | 0% | 300.9 | 120,356 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.26 per share. | 10 Feb 2023 | 5,990 | 86,890 (0%) | 0% | 298.3 | 1,786,577 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 294.33 per share. | 10 Feb 2023 | 3,372 | 92,880 (0%) | 0% | 294.3 | 992,481 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 298.42 per share. | 10 Feb 2023 | 2,028 | 84,617 (0%) | 0% | 298.4 | 605,196 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 299.26 per share. | 10 Feb 2023 | 1,779 | 82,838 (0%) | 0% | 299.3 | 532,384 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 300.13 per share. | 10 Feb 2023 | 835 | 82,003 (0%) | 0% | 300.1 | 250,609 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 296.44 per share. | 10 Feb 2023 | 245 | 86,645 (0%) | 0% | 296.4 | 72,628 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 14,624 | 85,043 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 12,388 | 70,419 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 11,209 | 96,252 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2022 | 12,753 | 58,031 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 304.67 per share. | 15 Aug 2022 | 6,990 | 52,226 (0%) | 0% | 304.7 | 2,129,643 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 305.38 per share. | 15 Aug 2022 | 6,948 | 45,278 (0%) | 0% | 305.4 | 2,121,780 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 155.57 per share. | 15 Aug 2022 | 6,571 | 67,451 (0%) | 0% | 155.6 | 1,022,250 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2022 | 6,571 | 0 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 301.61 per share. | 15 Aug 2022 | 4,242 | 61,955 (0%) | 0% | 301.6 | 1,279,430 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 303.78 per share. | 15 Aug 2022 | 2,339 | 59,216 (0%) | 0% | 303.8 | 710,541 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 300.30 per share. | 15 Aug 2022 | 1,254 | 66,197 (0%) | 0% | 300.3 | 376,576 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 302.55 per share. | 15 Aug 2022 | 400 | 61,555 (0%) | 0% | 302.6 | 121,020 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 300.32 per share. | 10 Aug 2022 | 171 | 60,889 (0%) | 0% | 300.3 | 51,355 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2022 | 64 | 6,571 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 155.56 per share. | 10 Aug 2022 | 64 | 61,060 (0%) | 0% | 155.6 | 9,956 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 302.00 per share. | 10 Aug 2022 | 9 | 60,880 (0%) | 0% | 302 | 2,718 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 300.53 per share. | 09 Aug 2022 | 4,790 | 61,896 (0%) | 0% | 300.5 | 1,439,539 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 155.57 per share. | 09 Aug 2022 | 1,926 | 66,686 (0%) | 0% | 155.6 | 299,628 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2022 | 1,926 | 6,635 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 301.42 per share. | 09 Aug 2022 | 900 | 60,996 (0%) | 0% | 301.4 | 271,278 | Common Stock |
| Immunogen, Inc. | Stuart A. Arbuckle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 44,000 | 44,000 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Stuart A. Arbuckle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 15,000 | 63,000 | - | - | Deferred Share Unit | |
| Rhythm Pharmaceuticals Inc. | Stuart A. Arbuckle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 254.20 per share. | 16 May 2022 | 40 | 64,760 (0%) | 0% | 254.2 | 10,168 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 250.78 per share. | 16 May 2022 | 32 | 64,820 (0%) | 0% | 250.8 | 8,025 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 249.35 per share. | 16 May 2022 | 20 | 64,852 (0%) | 0% | 249.4 | 4,987 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 246.18 per share. | 16 May 2022 | 11 | 64,882 (0%) | 0% | 246.2 | 2,708 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 252.70 per share. | 16 May 2022 | 10 | 64,800 (0%) | 0% | 252.7 | 2,527 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 251.40 per share. | 16 May 2022 | 10 | 64,810 (0%) | 0% | 251.4 | 2,514 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 248.00 per share. | 16 May 2022 | 10 | 64,872 (0%) | 0% | 248 | 2,480 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 263.98 per share. | 02 May 2022 | 306 | 64,760 (0%) | 0% | 264.0 | 80,778 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 227.86 per share. | 24 Feb 2022 | 7,246 | 65,066 (0%) | 0% | 227.9 | 1,651,074 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 232.51 per share. | 17 Feb 2022 | 4,126 | 72,312 (0%) | 0% | 232.5 | 959,336 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 237.74 per share. | 10 Feb 2022 | 3,040 | 76,438 (0%) | 0% | 237.7 | 722,730 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 14,623 | 79,478 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 13,952 | 64,855 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 9,800 | 50,903 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Stuart A. Arbuckle | EVP, COO | Sale of securities on an exchange or to another person at price $ 187.00 per share. | 15 Nov 2021 | 2 | 41,104 (0%) | 0% | 187 | 374 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges